PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 15, 2026Neuropsychiatric Disease and Treatment0 citationsOpen Access

Neurocognitive Effects of Blonanserin, Olanzapine, Aripiprazole, and Risperidone in Schizophrenia

Comparison of Neurocognitive Effects of Blonanserin, Olanzapine, Aripiprazole, and Risperidone in Drug-Naïve First-Episode Schizophrenia

View Full Paper
Ask AI
Bookmark
Share

Authors

WHWanheng HuBHBingjie HuangXGXiaoDong Guo

Discussion

Loading...

Member takes

Overview

Randomized trials compare neurocognitive outcomes in drug-naïve first-episode schizophrenia patients treated with various antipsychotics, indicating potential benefits of blonanserin.

Key Points

  • This research aims to investigate the neurocognitive effects of four antipsychotics in drug-naïve first-episode schizophrenia patients.
  • Data from two clinical trials were analyzed, involving drug-naïve first-episode schizophrenia patients receiving either blonanserin, olanzapine, aripiprazole, or risperidone.
  • Neurocognitive functions were assessed at baseline and after 6 months using multiple measures, with comparisons made using repeated measures ANOVA.
  • A total of 594 patients were recruited, with 294 completing follow-up assessments.
  • All groups showed significant improvements in processing speed and working memory over the treatment period.
  • A significant group-by-time interaction was found for verbal memory (p = 0.005) and visuospatial memory (p = 0.054).
  • Blonanserin-treated patients displayed greater improvements in verbal learning (p = 0.005) and visuospatial memory (p = 0.045) than those treated with risperidone.

Cite This Study

Hu et al. (2026) studied this question.

synapsesocial.com/papers/6a06b998e7dec685947ac548https://doi.org/10.2147/ndt.s603001
View Full Paper
Ask AI
Bookmark
Share